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ABSTRACT. We developed a combinatorial strategy aiming at designing peptide inhibitors against the hGSTP1-1 isoenzyme involved in MDR. 
We developed a combinatorial strategy aiming at designing peptide inhibitors against the hGSTP1-1 isoenzyme. We employed a combinatorial 
peptide library featuring engineered E. coli cells harboring a plasmid able to express a fusion protein containing random 12peptides. After five 
selection rounds, clones were screened for hGSTP1-1 binding (dot blot hybridization) and those with the strongest signal were selected and 
sequenced. Sequence alignments showed a core binding sequence which, along with selected peptide fragments, were synthesized using the 
solid phase methodology . The synthetic peptides were studied for their inhibition potency against three human GSTP1-1 allozymes, A, B and C 
INTRODUCTION. Glutathione S-transferases (GSTs, EC 2.5.1.18) are 
a large family of isoenzymes catalysing the conjugation of the 
tripeptide glutathione (GSH) to a variety of hydrophobic endogenous 
and exogenous compounds, rendering them hydrophilicity and 
facilitating their eventual secretion from the cell. They catalyse the 
conjugation of glutathione (GSH) to a variety of hydrophobic 
endogenous and exogenous substrates, rendering them hydrophilicity 
and facilitating their metabolic processing and eventual secretion from 
the cell [1]. Based on the same detoxification mechanisms, cancer cells 
may acquire resistance against certain chemotherapeutic drugs by 
overexpressing GST isoenzymes, mainly of the α, π and μ classes [2,3]. 
Therefore, there is an increasing interest for new GST synthetic 
inhibitors, as a strategy to eventually overcoming MDR attributed to 
GST overexpression[5-8]. We report on the design, synthesis and 
enzymological evaluation of peptides as inhibitors for hGSTP1-1 
allozymes A,B,C. 
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RESULTS/CONCLUSIONS. We developed a combinatorial 
strategy aiming at designing peptide inhibitors against the 
hGSTP1-1 isoenzyme (Figure 1). We employed a combinatorial 
peptide library featuring engineered E. coli cells harboring a 
plasmid able to express a fusion protein containing random 
12peptides which were inserted into the active loop of 
thioredoxin, which itself was inserted into the dispensable 
region of the flagellin gene (Figure 2) engineered to express a 
fusion protein containing random dodecapeptides that were 
inserted into the active loop of thioredoxin. When the fusion 
protein becomes an integral part of the flagellar filaments on the 
bacterial cell surface, the dodecapeptides become available to 
interact with target proteins. After 5 continuous selection rounds, 
different clones were screened for hGSTP1-1 binding  by dot blot 
(Figure 3) and the clones exhibiting the strongest signal were 
selected and their sequence determined by nucleotide 
sequencing. Sequence alignments showed a core binding 
sequence (TH10: PATAISLGGG) which, along with selected peptide 
fragments (TH5N: PATAI, TH5C: SLGGG, TH4: AISL), were 
synthesized using the solid phase methodology and Fmoc/tBu 
chemistry on 2-chlorotrityl chloride solid support.  
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Allozyme Substrate 
Vmax 
(μmol·min-1·mL-1) 
kcat 
(min-1) 
Km 
(mM) 
kcat/Km 
(min-1·mM-1) 
hGSTP1A 
GSH 0.028 1052 0.128 8237 
CDNB 0.069 2991 1.320 2265 
hGSTP1B 
GSH 0.017 458 0.149 3078 
CDNB 0.032 892 1.163 767 
hGSTP1C 
GSH 0.014 206 0.127 1615 
CDNB 0.023 457 1.069 427 
 
Peptide 
Inhibition of hGSTP1-1  
(%, compared in the absence of inhibitor) 
A B C 
TH10 :  
32.2 
 
58.0 
 
25.4 
TH5N : 29.2 46.6 14.3 
TH5C : 
 
34.2 42.2 18.7 
TH4 : 15.0 30.6 16.8 
1. Oakley, A. J. Drug Metab. Rev. 2011, 43, 138.  
2. Morrow, C.S., Smitherman P.K., Townsend A.J. Biochem. Pharmacol., 1998, 56, 1013. 
3. Sau, A.; Trengo, F. P.; Valentino, F.; Federici, G.; Caccuri, A. M. Arch. Biochem. Biophys. 2010, 500, 116. 
4. Mahajan, S.; Atkins, W. M. Cell. Mol. Life Sci. 2005, 62, 1221. 
5. Adang, A. E.; Brussee, J.; van der Gen, A.; Mulder, G. J. J. Biol. Chem. 1991, 266, 830. 
6. Koutsoumpli, G. E., Dimaki, V. D., Thireou, T. N., Eliopoulos, E. E., Labrou, N. E., Varvounis, G. I., Clonis, Y. D.  J. Med. Chem. 2012, 55, 6802. 
7. Zoi, O.G.; Thireou, T.N.; Rinotas, V.E. ; Tsoungas, P.G.; Eliopoulos, E.E.; Douni, E.K.; Labrou, N.E. and Clonis, Y.D. J. Biomol. Screen., 2013, 18, 1092.  
8. Perperopoulou F.D., Tsoungas P.G., Thireou T.N., Rinotas V.E., Douni E.K., Eliopoulos E.E., Labrou N.E. and Clonis Y.D. Bioorg. Med. Chem., 2014, 22, 3957. 
Table 1. Kinetic constants for hGSTP1 allozymes A, B & C. 
Table 2. Inhibition of hGSTP1 allozymes by peptides designed on the 
basis of results from the E. coli  displayed combinatorial library.  
Figure 1. Schematic representation of the 
strategy employed for the combinatorial 
design and characterization of peptide 
inhibitors towards hGSTP1-1.  
The purified allozymes were subjected to kinetic study and 
inhibition tests with the designed peptides TH10, TH5N, TH5C & TH4.  
 It appears that the mutations of the allozymes hGSTP1*A 
(Ile104/Ala113), hGSTP1*B (Val104/Ala113) & hGSTP1*C (Val104/Val113) 
have small influence on the binding affinity between substrate & 
enzyme (Table 1, Km values), but result in significant changes of the 
reaction rate (Table 1, kcat values) and, hence, the overall catalytic 
efficiency (Table 1, kcat /Km values).  Furthermore, these mutations 
influence the inhibitory ability of the designed peptides. TH10 is the 
most effective inhibitor (Table 2), with the shorter counterparts 
showing varied inhibitory potency depending on the allozyme (Table 
2).   
↓
 The structure of hGSTP1-1 
